Evan David Seigerman
Stock Analyst at BMO Capital
(3.81)
# 913
Out of 5,182 analysts
55
Total ratings
56.25%
Success rate
8.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Outperform | $120 → $100 | $67.26 | +48.68% | 2 | Feb 17, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $82 → $130 | $110.03 | +18.15% | 5 | Dec 18, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $731.77 | +16.16% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $339.57 | +9.55% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $41.17 | +11.73% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $2.57 | +328.02% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $197.69 | +21.40% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $27.45 | -5.28% | 2 | Jun 12, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $22.67 | +23.51% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $10.22 | -2.15% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $43.56 | +129.57% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $26.48 | +35.95% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $6.20 | -51.61% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $874.00 | -54.69% | 1 | Sep 6, 2022 |
Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $120 → $100
Current: $67.26
Upside: +48.68%
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82 → $130
Current: $110.03
Upside: +18.15%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $731.77
Upside: +16.16%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $339.57
Upside: +9.55%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $41.17
Upside: +11.73%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $2.57
Upside: +328.02%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $197.69
Upside: +21.40%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $27.45
Upside: -5.28%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $22.67
Upside: +23.51%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $10.22
Upside: -2.15%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $43.56
Upside: +129.57%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $26.48
Upside: +35.95%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $6.20
Upside: -51.61%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $874.00
Upside: -54.69%